Pegaptanib
- Generic Name
- Pegaptanib
- Drug Type
- Biotech
- CAS Number
- 222716-86-1
- Unique Ingredient Identifier
- 3HP012Q0FH
- Background
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.
- Indication
For the treatment of neovascular (wet) age-related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-05-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 4
- Registration Number
- NCT00346983
- Locations
- 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
- Conditions
- Age Related Macular Degeneration (AMD)Macular DegenerationChoroidal Neovascularization (CNV)
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 288
- Registration Number
- NCT00327470
- Locations
- 🇬🇧
Pfizer Investigational Site, Southampton, United Kingdom
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2010-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT00324116
- Locations
- 🇫🇷
Pfizer Investigational Site, Toulouse, France
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2006-05-04
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00321997
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
- Conditions
- Macular Degeneration
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 262
- Registration Number
- NCT00312351
- Locations
- 🇺🇸
Charlotte Eye, Ear, Nose and Throat Associates, P.A., Charlotte, North Carolina, United States
Macugen for Histoplasmosis
- Conditions
- Ocular HistoplasmosisChoroidal Neovascularization
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2006-10-27
- Lead Sponsor
- Barnes Retina Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00272766
- Locations
- 🇺🇸
Barnes Retina Institute, St. Louis, Missouri, United States
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
- Conditions
- Macular DegenerationChoroidal Neovascularization
- Interventions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT00242580
- Locations
- 🇺🇸
Novartis Investigational Site, Austin, Texas, United States
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00239928
- Locations
- 🇯🇵
Pfizer Investigational Site, Kyoto, Japan
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT00215670
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
- Conditions
- Macular Degeneration
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00150202
- Locations
- 🇯🇵
Pfizer Investigational Site, Kyoto, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.